A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Trial ID or NCT#
NCT00186433
Status
NOT RECRUITING
Purpose
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.
Official Title
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Having a new diagnosis of Nasopharyngeal carcinoma.* Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion Criteria:
- * Age \<18 since NPC is a very rare condition in this age group and may have a different biological behavior* Patients who are unable to provide informed consents for themselves.
Investigator(s)
Quynh-Thu Le, MD
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
James L. Zehnder, M.D.
Hematologist,
Pathologist
Professor of Pathology (Research) and of Medicine (Hematology)
Harlan Pinto
Medical oncologist,
Head and neck specialist
Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery
Billy W Loo, Jr, MD PhD FASTRO FACR
Radiation oncologist,
Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy)
Contact us to find out if this trial is right for you.
Contact
Quynh-Thu Le
650-498-6184
View on ClinicalTrials.gov
